BioMarin Pharmaceutical Inc. annual operating income for fiscal 2025 was $410 million, a decrease of 13.6% from $474 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Income (EBIT) | $410M | $474M | $186M | $57M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $130M | ($45M) | ($47M) | $277M | $224M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BMRN metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow
All BMRN financial statements → Interactive BMRN charts →
About TickerBase · Data methodology & sources